OHPC has been used to treat [[benign prostatic hyperplasia]] in men, although evidence of effectiveness is marginal and uncertain.<ref name="Springer2012">{{cite book|title=Benign Prostatic Hypertrophy|url=https://books.google.com/books?id=Z5K-BwAAQBAJ&pg=PA266|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-1-4612-5476-8|pages=266–}}</ref> The mechanism of action of OHPC in this use is suppression of testicular androgen production via suppression of [[luteinizing hormone]] secretion, which are the result of the progestogenic and [[antigonadotropic]] activity of OHPC.<ref name="Springer2012" /> However, symptoms of [[hypogonadism]] may develop when OHPC is used for this indication, with two-thirds of men reportedly experiencing [[impotence]].<ref name="Aronson2009">{{cite book|author=Jeffrey K. Aronson|title=Meyler's Side Effects of Endocrine and Metabolic Drugs|url=https://books.google.com/books?id=BWMeSwVwfTkC&pg=PA289|date=21 February 2009|publisher=Elsevier|isbn=978-0-08-093292-7|pages=289–}}</ref>

 
Through activation of the PR, OHPC has the potential for [[antigonadotropic]] effects,<ref name="pmid8082440">{{cite journal | vauthors = Yang D, Zhu RL | title = [Changes in reproductive hormones levels in the treatment of endometrial precancerous lesion with hydroxyprogesterone caproate] | language = Chinese | journal = Zhonghua Fu Chan Ke Za Zhi | volume = 29 | issue = 4 | pages = 205–6, 251 | year = 1994 | pmid = 8082440 | doi = | url = | quote = In this paper, 14 cases of precancerous lesion of endometrium were treated with hydroxyprogesterone caproate and a series of hormone determination was analysed before and after treatment. Results showed that LH and LH/FSH were dramatically decreased. (LH P < 0.05, LH/FSH P < 0.01).}}</ref><ref name="Springer2012B">{{cite book|title=Benign Prostatic Hypertrophy|url=https://books.google.com/books?id=Z5K-BwAAQBAJ&pg=PA266|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-1-4612-5476-8|pages=266–|quote=Since the initial report by Geller and associates28 on the use of hydroxyprogesterone caproate in the treatment of BPH, a variety of progestins have been studied in the medical management of this disease: hydroxyprogesterone caproate, chlormadinone acetate,27 and medrogestone (6-methyl-6-dehydro-17-methylprogesterone).50 These drugs should have a beneficial effect in BPH as they inhibit testicular function by suppressing serum LH and have no intrinsic estrogenic or androgenic activity.}}</ref> and can significantly suppress [[gonadotropin]] [[secretion]] and gonadal [[sex hormone]] production at sufficiently high dosages.<ref name="Castro2013">{{cite book|author=J.E. Castro|title=The Treatment of Prostatic Hypertrophy and Neoplasia|url=https://books.google.com/books?id=Nc8hBQAAQBAJ&pg=PA39|date=9 March 2013|publisher=Springer Science & Business Media|isbn=978-94-015-7190-6|pages=39–|quote=Geller has also demonstrated significant decreases in plasma or urine testosterone glucuronide levels following the administration of three other anti-androgens. These include Delalutin [hydroxyprogesterone caproate], chlormadinone acetate, and PH-218. It would appear that decreased androgen production is a property shared by all anti-androgens to date.}}</ref> One study found that 400&nbsp;mg/week intramuscular OHPC suppressed [[luteinizing hormone]] and [[follicle-stimulating hormone]] levels in men by 24–30% and 19–55%, respectively.<ref name="pmid65818">{{cite journal | vauthors = Meiraz D, Margolin Y, Lev-Ran A, Lazebnik J | title = Treatment of benign prostatic hyperplasia with hydroxyprogesterone-caproate: placebo-controlled study | journal = Urology | volume = 9 | issue = 2 | pages = 144–8 | year = 1977 | pmid = 65818 | doi = 10.1016/0090-4295(77)90184-4| url = }}</ref> In another study that used an unspecified dosage of intramuscular OHPC, testosterone secretion was assessed in a single patient and was found to decrease from 4.2&nbsp;mg/day to 2.0&nbsp;mg/day (or by approximately 52%) after six weeks of treatment, whereas secretion of luteinizing hormone remained unchanged in the patient.<ref name="pmid14304354">{{cite journal | vauthors = GELLER J, BORA R, ROBERTS T, NEWMAN H, LIN A, SILVA R | title = Treatment of benign prostatic hypertrophy with hydroxyprogesterone caproate: effect on clinical symptoms, morphology, and endocrine function | journal = JAMA | volume = 193 | issue = | pages = 121–8 | year = 1965 | pmid = 14304354 | doi = 10.1001/jama.1965.03090020035009| url = }}</ref>

 
As a pure progestogen,<ref name="Geller1965">{{cite journal|last1=Geller|first1=Jack|title=Treatment of Benign Prostatic Hypertrophy With Hydroxyprogesterone Caproate|journal=JAMA|volume=193|issue=2|year=1965|pages=121|issn=0098-7484|doi=10.1001/jama.1965.03090020035009|pmid=14304354}}</ref> OHPC has no [[androgen]]ic or [[glucocorticoid]] properties,<ref name="pmid15863556">{{vcite2 journal | vauthors = Meis PJ | title = 17 hydroxyprogesterone for the prevention of preterm delivery | journal = Obstet Gynecol | volume = 105 | issue = 5 Pt 1 | pages = 1128–35 | year = 2005 | pmid = 15863556 | doi = 10.1097/01.AOG.0000160432.95395.8f | url = }}</ref> nor any [[estrogen]]ic effects.<ref name="Geller1965" /> Due to its lack of androgenic properties, similarly to progesterone, OHPC does not have any [[teratogen]]ic effects on the [[fetus]], making it safe for use during [[pregnancy]].<ref name="pmid15863556" /> In relation to glucocorticoid activity, OHPC has been found not to alter [[cortisol]] levels in humans even with extremely high dosages via [[intramuscular injection]],<ref name="OnsrudPaus1985">{{cite journal|last1=Onsrud|first1=Mathias|last2=Paus|first2=Elisabeth|last3=Haug|first3=Egil|last4=Ørstad|first4=Kjell K|title=Intramuscular Administration of Hydroxyprogesterone Caproate in patients with Endometrial Carcinoma: Pharmacokinetics and effects on adrenal function|journal=Acta Obstetricia et Gynecologica Scandinavica|volume=64|issue=6|year=1985|pages=519–523|issn=0001-6349|doi=10.3109/00016348509156732}}</ref> which is of relevance because drugs with significant glucocorticoid activity suppress cortisol levels (due to increased [[negative feedback]] on the [[hypothalamic-pituitary-adrenal axis]]). OHPC has been studied in humans at dosages as high as 5,000&nbsp;mg per week via intramuscular injection (in the treatment of [[endometrial cancer]] specifically, with safety and effectiveness observed).<ref name="Varga1961">Varga A, Henriksen E. Clinical and Histopathologic Evaluation of the Effect of 17-alpha-Hydroxyprogesterone-17-n-caproate on Endometrial Carcinoma. Obstetrics & Gynecology. December 1961. Volume 18. Issue 6. pp. 658-672.</ref>

 
Along with [[hydroxyprogesterone acetate]], OHPC was developed by Karl Junkmann of [[Schering AG]] in 1953 and was first reported by him in the [[medical literature]] in 1954.<ref name="DavisReprints">{{cite book|author=M. Edward Davis|title=M. Edward Davis Reprints|url=https://books.google.com/books?id=xg8iAQAAMAAJ|page=406|quote=Chemically pure progesterone was the only substance with progestational properties in general use which could be administered parenterally until Junkmann (1) developed in 1953, 17-alpha-hydroxyprogesterone acetate and 17-alpha-hydroxyprogesterone caproate.}}</ref><ref name="pmid13583817">{{cite journal | vauthors = WIED GL, DAVIS ME | title = Comparative activity of progestational agents on the human endometrium and vaginal epithelium of surgical castrates | journal = Ann. N. Y. Acad. Sci. | volume = 71 | issue = 5 | pages = 599–616 | year = 1958 | pmid = 13583817 | doi = 10.1111/j.1749-6632.1958.tb46791.x| url = | quote = In the group of new parenteral progestational agents, three substances developed by Karl Junkmann1,2 are the most outstanding and interesting: 17a-hydroxyprogesterone caproate and 17a-hydroxyprogesterone acetate, introduced in 1953, and the most potent of all new parenteral progestational agents, 17-ethynyl-19-nortestosterone enanthate, introduced in 1956.}}</ref><ref name="ACRH1960">{{cite book|title=ACRH|url=https://books.google.com/books?id=HQVYAAAAYAAJ|year=1960|publisher=U.S. Dept. of Energy|page=71|quote=[The] minimal activity [of 17(a)-hydroxyprogesterone] is magnified to an unexpected degree by the esterification of this steroid with caproic acid to produce 17(a)-hydroxyprogesterone-17-n-caproate, first reported by Karl Junkmann in 1954.6,7}}</ref><ref name="Dorfman1966">{{cite book|author=Ralph Isadore Dorfman|title=Methods in Hormone Research|url=https://books.google.com/books?id=mQVHAAAAYAAJ|year=1966|publisher=Academic Press|page=86|quote=Junkmann (1954) reported that the acetate, butyrate, and caproate forms had both increased and prolonged activity, [...]}}</ref><ref name="Applezweig1962">{{cite book|author=Norman Applezweig|title=Steroid Drugs|url=https://books.google.com/books?id=SIhLAAAAYAAJ|year=1962|publisher=Blakiston Division, McGraw-Hill|pages=101–102|quote=Junkmann of Schering, AG., however, was able to show that long chain esters of 17a-hydroxyprogesterones such as the 17a-caproate produced powerful long-acting progestational effect. This compound is marketed in the United States as Delalutin by Squibb, and has been heavily used for the treatment of habitual abortion.}}</ref> It was reportedly first marketed in [[Japan]] in 1954 or 1955,<ref name="Cancer1979">{{cite book|author=International Agency for Research on Cancer|title=Sex Hormones (II).|url=https://books.google.com/books?id=nrhrAAAAMAAJ|year=1979|publisher=International Agency for Research on Cancer|isbn=978-92-832-1221-8|page=401|quote=17α-Hydroxyprogesterone caproate was first marketed commercially in Japan in 1954-1955.}}</ref> and was subsequently introduced as '''Delalutin''' in the [[United States]] in 1956. After decades of use, [[Squibb]], the manufacturer, voluntarily withdrew the brand, however, physicians continued to use OHPC "[[off-label]]". Renewed interest was sparked with a large NIH-sponsored study in 2003 that found that OHPC reduced the risk of premature birth in selected at-risk pregnant women.<ref name=nih2003/> With follow-up data showing no evidence of harmful effects on the offspring, the FDA approved the drug, as sponsored by [[KV Pharmaceutical]] as '''Makena''', as an [[orphan drug]] in February 2011 to reduce the risk of premature birth in women prior to 37 weeks gestation with a single fetus who had at least one previous premature birth.<ref>[http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm242234.htm FDA press release regarding Makena approval]</ref> The drug is not effective in preventing premature birth in women with multiples. With the arrival of Makena as an orphan drug, the price of the drug was to increase from $15 to $1,500 per dose meaning a typical treatment would cost $25–30,000, - a pricing strategy that was strongly [[Makena pricing controversy|criticized]]. The FDA then announced that pharmacies could continue to compound the drug at their usual cost of $10~20 per dose without fear of legal reprisals.,<ref>http://www.macleans.ca/article.jsp?content=w6411446</ref> and KV reduced its price to $690 per dose.<ref>{{cite news |url=http://www.boston.com/news/nation/washington/articles/2011/04/02/price_of_preterm_birth_medicine_cut/| publisher=Boston.com |agency=Associated Press| title=Price of preterm birth medicine cut |date=April 2, 2011 |accessdate=April 2, 2011}}</ref>
